Ruxolitinib: Second-Line Treatment for Bronchiolitis Obliterans
Ruxolitinib has emerged as a potential game-changer in the treatment landscape of bronchiolitis obliterans syndrome (BOS), particularly in patients who ...
Ruxolitinib has emerged as a potential game-changer in the treatment landscape of bronchiolitis obliterans syndrome (BOS), particularly in patients who ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine